Mucosal Vaccines, Adjuvants & Delivery

25-27 September 2013, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 26th September

SESSION 5:
ADJUVANTS

Moderator: Jan Holmgren (Gothenburg University, Gothenburg, Sweden)

09.00-09.25
‘T-cell dependencies for IgA induction by CAF01’
Dennis Christensen (States Serum Institut, Copenhagen, Denmark)

09.25-09.50
‘Toxin derivatives and other danger signals as mucosal adjuvants’
John Clements (Tulane University, New Orleans, Louisiana, USA)

09.50-10.10
‘A novel non-toxic cholera toxin mutant adjuvant produced in Vibrio cholerae
Michael Lebens, S. Kallgard, M. Terrinoni, S. Karlsson, E. Ax, M. Blomquist, A. Ekman, T. Gustafsson, M. Larena and J. Holmgren (University of Gothenburg, Gothenburg, Sweden)

10.10-10.30
‘Adjuvant effects and mechanisms of dmLT and related molecules on human immune cells’
Maximilian Larena, Anna Lundgren, Jan Holmgren and Susannah Leach (University of Gothenburg, Gothenburg, Sweden)

10.30-10.50
‘Novel candidate adjuvants for tailoring immune responses’
Sebastian Weissmann, Thomas Ebensen, Kai Schulze and Carlos A. Guzman (Helmholz Centre for Infection Research (HZI), Braunschweig, Germany)

10.50-11.10
‘Improved immunogenicity with DNA-based cytokine and chemokine adjuvants delivered using in vivo electroporation’
Kate E. Broderick, Amir S. Khan, Matthew P. Morrow and Niranjan Y. Sardesai (Inovio Inc., Blue Bell, Pennsylvania, USA)

11.10-11.40
Coffee Break & Posters

SESSION 6:
INFLUENZA I

Moderator: Ted Ross (Vaccine and Gene Therapy Institute, Port St. Lucie, Florida, USA)

11.40-12.00
‘Immunose™ FLU a nasal influenza vaccine conferring complete protection in influenza naive ferrets’
Anna-Karin Maltais, Jorma Hinkula, Alf Lindberg, Hans Arwidsson, Koert J. Stittelaar and Albert D.M.E. Osterhaus (Eurocine Vaccines AB, Solna, Sweden)

12.00-12.20
‘Human clinical trials results for an oral adjuvanted adenoviral vaccine for the prevention of seasonal influenza’
Sean Tucker (Vaxart Inc., San Francisco, California, USA)

12.20-12.40
‘Mucosal adjuvant SF-10, mimicking pulmonary surfactant, for nasal vaccinations of influenza virus and RSV: Safety and efficacy in mice and rhesus macaques’
Hiroshi Kido, Dai Mizuno and Takashi Kimoto (The University of Tokushima, Tokushima, Japan)

12.40-13.00
‘Comparison of adjuvants for the development of a spray freeze dried whole inactivated virus influenza vaccine for pulmonary administration’
Anke Huckriede, P. Harshad, P. Patil, Senthil Murugappan, Jacqueline de Vries-Idema, Tjarko Meijerhof, Jan Wilschut, Henderik W. Frijlink and Wouter L.J. Hinrichs (University of Groningen, Groningen, The Netherlands)

13.00-14.00
Lunch Break & Posters

SESSION 7:
DELIVERY

Moderator: Dennis Christensen (States Serum Institut, Copenhagen, Denmark)

14.00-14.30
‘Mucosal immune responses after I.M. vaccination’
David B. Weiner (University of Pennsylvania, Philadelphia, Pennsylvania, USA)

14.30-14.50
In vivo evaluation of the efficacy of intradermal and intramuscular gene vaccine delivery’
Stefan Petkov, Elizaveta Starodubova, Frank Heuts, Olga Krotova, Athina Kilpelainen, Gunnel Engstrom, Britta Wahren and Maria Isaguliants (Karolinska Institutet, Stockholm, Sweden)

14.50-15.15
‘A skin-deep approach to mucosal vaccines’
Anne Moore (University College Cork, Cork, Ireland)

15.15-15.35
‘Polyelectrolyte microparticles as biometric mucosal delivery vehicles facilitate antigen presentation by dendritic cells’
Bert Devriendt, Kim Baert, Marijke Dierendonck, Herman Favoreel, Jean Paul Remon, Bruno G. de Geest and Eric Cox (University of Ghent, Ghent, Belgium)

15.35-15.55
‘Sampling and intralymphatic trafficking of inert microparticles by mucosal dendritic cell subsets’
Nicholas J. Mantis, Magdia De Jesus, Gary Ostroff and Stuart M. Levitz (Wadsworth Center, Albany, New York, USA)

15.55-16.15
Tea Break and Posters

SESSION 8:
MUCOSAL VACCINES

Moderator: Maarten van Roosmalen (Mucosis BV, Groningen, The Netherlands)

16.15-16.35
‘Regulatory and CMC challenges for mucosal vaccines’
Brijesh Patel (RegExcel (former MHRA assessor), London, UK)

16.35-17.00
‘Respiratory infections: Protection by systemic and/or mucosal immunity?
Sylvain Fleury (Mymetics Corporation, Epalinges, Switzerland)

17.00-17.20
‘Expression of bacterial adhesions on the spore coat enhances the immunogenicity of Bacillus subtilis endospores as orally-delivered vaccine vectors against the oral pathogen Streptococcus mutans
Milene Batista Tavares, Juliano D. Paccez, Renata D. Souza, Rafael C.M. Cavalcante, Wilson B. Luiz, Rita C.C. Ferreira and Luis C.S. Ferreira (University of Sao Paulo, Sao Paulo, Brazil)

17.20-17.40
‘ELIspot on enriched IgA+ B-lymphocytes can be used to detect the IgA response following oral immunization with F4 fimbriae of pigs with colostral F4-specific serum antibodies’
V.U. Nguyen, V. Melkebeek, T. Goetstouwers, M. van Poucke, L. Peelman, B.M. Goddeeris and E. Cox (Ghent University, Ghent, Belgium)

 

MUCOVAD 2013 Delegates

Login details will be supplied after you have registered for the event.


MUCOVAD 2013 Sponsors

  • Inovio Pharmaceuticals
  • Nature Gene Therapy
  • DNA Vaccine
  • Izon
  • PATH
  • Univac
  • Mucosis
  • Aldevron
  • Pevion Vaccines
  • Current Drug Delivery
  • Biovaxx
  • Drug Delivery Letters
  • Retroscreen Virology
  • Eurocine Vaccines
  • Sanofi Pasteur
  • Immune Solutions

MUCOVAD 2013 Downloads

MUCOVAD 2013 Leaflet

MUCOVAD 2013 Mailing List

Name
E-mail Address
What is 1+4-2?